Skip to content

LAAO With DAPT Versus Antithrombotic Therapy

Comparison of Clinical Outcomes Between Left Atrial Appendage Occlusion With Dual Antiplatelet Therapy Versus Conventional Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-eluting Stent Implantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03310801
Enrollment
480
Registered
2017-10-16
Start date
2016-08-01
Completion date
2017-08-30
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Coronary Artery Disease

Keywords

left atrial appendage occlusion, antithrombotic therapy, atrial fibrillation, percutaneous coronary intervention, drug eluting stent

Brief summary

This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.

Detailed description

Composite of stroke and major bleeding will be compared after adjusting those groups using inverse probability weighted model.

Interventions

PROCEDUREACP or Watchman

Left atrial appnedage occlusion using ACP or Watchman

Sponsors

Severance Hospital
CollaboratorOTHER
Sejong General Hospital
CollaboratorOTHER
Gachon University Gil Medical Center
CollaboratorOTHER
Ulsan University Hospital
CollaboratorOTHER
Korea University Anam Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients with AF who underwent PCI and treated with LAAO and DAPT or conventional antithrombotic therapy

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Composite of stroke and major bleedingFrom date of index procedure until the date of primary endpoint occur or date of last follow up, whichever came first, assessed up to 50 monthsPrimary endpoint is a composite of stroke and major bleeding. Stroke is defined as ischemic cerebrovascular event included both transient ischemic attack and ischemic cerebral infarction. Major bleeding event was defined as moderate or severe bleeding according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026